InvestorsHub Logo
Followers 21
Posts 1118
Boards Moderated 0
Alias Born 09/07/2012

Re: dmort545 post# 60

Tuesday, 02/07/2017 12:15:30 PM

Tuesday, February 07, 2017 12:15:30 PM

Post# of 3159
Can you sticky the news ?

http://finance.yahoo.com/news/q-biomed-joins-oklahoma-medical-130000575.html

NEW YORK, February 7, 2017 /PRNewswire/ --

Q BioMed, Inc. (QBIO) has entered into an agreement with the Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB) to develop a chemotherapeutic technology to treat liver cancer.

The technology will utilize "uttroside B" and the compound's derivatives as a chemotherapeutic agent against hepatocellular carcinoma. The preclinical efficacy of uttroside B, a potent saponin, against liver cancer was recently demonstrated in a November 3, 2016 study published in Scientific Reports, a Nature journal.

The compound has been isolated and characterized from the leaves of Solanum nigrum Linn, a plant widely used in traditional medicine. In the Scientific Reports study, researchers showed that in animal models, uttroside B was ten times more cytotoxic to the HepG2 liver cancer cell line than the only drug currently approved by the Food and Drug Administration for liver cancer.